Partners
- Home
- Partners
-
UCB
UCB Pharma S.A.
(EFPIA member company)UCB
-
is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB has operations in approximately 40 countries and global revenue of € 3.4 billion in 2012. UCB has drugs in development for the treatment of Rheumatoid Arthritis and SLE. UCB is committed to the development of disease modifying drugs for auto-immune diseases. The leadership for this IMI project is drawn from Department of Global Exploratory Development who are based in the UK and Belgium.
-
Coordinator, Leader of WP1, Co-leader of WP6 and WP9 , Participant in WP2, WP4, WP7, and WP8.
-
-
FPS
Fundación Pública Andaluza Progreso y Salud (GENYO)
FPS
-
is a mixed centre with stakes held by the Regional Ministry of Economy, Innovation, Science and Employment, the Regional Ministry of Equality, Health and Social Policies, the University of Granada and the pharmaceutical company Pfizer. This centre has been devised as a space for excellence research in genomic medicine, focussing on the comprehensive study and understanding of the genetic basis of human diseases in general, placing special emphasis on cancer and its genetic disorders related to inheritance. This centre is the benchmark centre of the Andalusian Program for Research in Clinical Genetics and Genomic Medicine, a program which, together with those of Cell Therapy and Regenerative Medicine, and Nanomedicine have the main objective of supporting and fostering translational research in Advanced Therapies. The activities performed within these three research programs are developed in coordination with the Andalusian Initiative for Advanced Therapies (IATA), an initiative of the Andalusian Government promoted by the Regional Ministries of Health and Innovation, Science and Enterprise.
-
Managing Entity, Leader of WP2 and WP9, Co-leader WP1, Participant in WP4, WP5, WP6, and WP8.
-
-
Althia
Althia Health, S.L.
(SME)Althia
-
is a company dedicated to the Personalised Predictive Oncology. Althia specializes in generating knowledge to improve the comprehensive management of cancer patients. Operates in three areas: 1) Clinical Diagnostics/Prognostics Services in hematological and solid tumors, to public and private hospitals, and laboratories; 2) R&D translational projects in collaboration with leading centers to identify molecular patterns in order to allow selection of patients responding to a given therapy; and 3) treatment by single dose image-guided radiation therapy (SD-IGRT), being implemented at the facilities of the Hospital Recoletas Campo Grande.
-
Participant in WP1, WP7, and WP9.
-
-
CHP
Centro Hospitalar do Porto. UMIB
CHP
-
Centro Hospitalar do Porto. UMIB, Instituto de Ciência Biomédicas Abel Salazar. Universidade do Porto. UMIB is based in a Medical School, the Institute of Biomedical Sciences Abel Salazar, University of Porto and its University Hospital, the Hospital de Santo António at Centro Hospitalar do Porto. To achieve its goals UMIB has multidisciplinary teams of researchers from different branches of basic science and clinical medicine, with diverse technical and scientific skills, which guarantee the possibility of using different approaches to achieve a common objective, thus creating the basis for the establishment of Translational Research programs.
-
Participant in WP1, WP2, WP3, WP5, and WP9.
-
-
CSIC
Consejo Superior de Investigaciones Científicas
CSIC
-
is the largest public institution dedicated to research in Spain and the third largest in Europe. Belonging to the Spanish Ministry of Economy and Competitiveness through the Secretary of State for Research, Development and Innovation, its main objective is to develop and promote research that will help bring about scientific and technological progress, and it is prepared to collaborate with Spanish and foreign entities in order to achieve this aim. The Institute of Parasitology and Biomedicine López-Neyra (IPBLN) forms part of the Spanish National Research Council (CSIC) and its activity is devoted to research in the area of biomedical sciences. The fields of research cover a wide range of issues concerning immunology, cell biology, molecular biology and pharmacology of important world-wide biomedical problems.
-
Leader of WP4, Participant in WP1, WP8, and WP9.
Institute of Parasitology and Biomedicine López-Neyra
-
-
IDIBELL
Fundacio Institut D'investigacio Biomedica De Bellvitge
IDIBELL
-
Bellvitge Biomedical Research Institute (IDIBELL) is a research centre focused on cellular medicine, where the high-level basic research focuses and works on relevant clinical matters and fosters economic development.IDIBELL is a foundation created in 2004 from the merger of several research entities. The centre manages the research of the Bellvitge University Hospital, the Institut Català d’Oncologia (Catalan Institute of Oncology) and the University of Barcelona. The Institute is integrated at Biopol’H area.In 2009, it became one of the first five Spanish research centres accredited as health research institute by the Instituto de Salud Carlos III (Health Institute Carlos III).
-
Participant in WP1, WP4, WP5, WP8, and WP9.
-
Project Partners
-
UCB
UCB Pharma S.A.
(EFPIA member company) -
FPS
Fundación Pública Andaluza Progreso y Salud (GENYO)
-
Althia
Althia Health, S.L.
(SME) -
CHP
Centro Hospitalar do Porto. UMIB
-
CSIC
Consejo Superior de Investigaciones Científicas
-
IRCCS
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
IDIBELL
Fundacio Institut D'investigacio Biomedica De Bellvitge
-
SCS
Servicio Cantabro de Salud Hospital Universitario Marqués de Valdecilla